Details

Autor(en) / Beteiligte

• Byrski, T.
• Gronwald, J.
• Huzarski, T.
• Grzybowska, E.
• Budryk, M.
• Stawicka, M.
• Mierzwa, T.
• Szwiec, M.
• Wiśniowski, R.
• Siolek, M.
• Narod, S. A.
• Lubinski, J.

Titel

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

Ist Teil von

• Breast cancer research and treatment, 2008-03, Vol.108 (2), p.289-296

Ort / Verlag

Boston: Springer US

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose There have been no studies to date which look at the relative effectiveness of different regimens of chemotherapy in women who have breast cancer and who carry a BRCA1 germ-line mutation. We wished to compare rates of response to neo-adjuvant chemotherapy in BRCA1 mutation carriers and non-carrier controls. Experimental design From a registry of 3,479 patients, we identified 44 Polish women who carried a BRCA1 founder mutation and who had been treated with neo-adjuvant chemotherapy for breast cancer, and 41 age- and hospital-matched controls. Results 35 of the 44 BRCA1 mutation carriers (80%) experienced a partial or complete response to neo-adjuvant chemotherapy, compared to 39 of the 41 (95%) non-carriers ( P  = 0.05). In the hereditary subgroup, response rates differed depending on whether or not a taxane (docetaxel) was given. Six of the 15 BRCA1 carrier women given docetaxel with doxorubicin responded (complete or partial), compared to 29 of 29 given other (DNA-damaging) therapies ( P  = 0.001). Among the non-carriers, the rates of response to the two categories of chemotherapy were similar. Conclusions Breast cancers among BRCA1 carriers frequently do not exhibit sensitivity to docetaxel in the neo-adjuvant setting. It is likely that normal BRCA1 is required for clinical response to mitotic spindle poisons.